Inhibition of tenascin-C expression in mammary epithelial cells by thyroid hormone

Molecular Carcinogenesis

Volumn 24, Issue 2, 1999, Pages 99-107

  González Sancho, José Manuel ^a   Alvarez Dolado, Manuel ^a   Caelles, Carme ^a   Muñoz, Alberto ^a  

^a CSIC   (Spain)

Author keywords

Breast cancer; ErbA; Mammary epithelial cells; Tenascin C; Thyroid hormone

Indexed keywords

DEXAMETHASONE; ESTRADIOL; LEVOTHYROXINE; MESSENGER RNA; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; TENASCIN; THYROXINE;

ANIMAL CELL; ARTICLE; BREAST CARCINOGENESIS; BREAST CARCINOMA; CANCER GROWTH; DOWN REGULATION; GENE EXPRESSION REGULATION; HORMONAL REGULATION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; PROTEIN SYNTHESIS REGULATION; RECEPTOR DENSITY; TUMOR VASCULARIZATION;

ANIMALIA;

EID: 0345434913     PISSN: 08991987     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1098-2744(199902)24:2<99::aid-mc4>3.0.co;2-%23     Document Type: Article

References (64)

1. Beatson GT. On the treatment of inoperable cases of carcinoma of the mamma: Suggestions for a new method of treatment, with illustrative cases. Lancet 1896;2:104-107.
2. Vorherr H. Thyroid function in benign and malignant breast disease. Eur J Cancer Clin Oncol 1987;23:255-257.
3. Goldman MB, Monson RR, Maloof F. Benign thyroid diseases and the risk of death from breast cancer. Oncology 1992;49:461-466.
4. Guernsey DL. Thyroid hormone action. Cancer J 1993;6:253-256.
5. Smyth PPA, Smith DF, McDermott EWM, Murray MJ, Geraghty JG, O'Higgins. A direct relationship between thyroid enlargement and breast cancer. J Clin Endocr Metab 1996;81:937-941.
6. Yokoe T, Iino Y, Takei H, et al. Changes of cytokines and thyroid function in patients with recurrent breast cancer. Anticancer Res 1997;17:695-700.
7. Strain JJ, Bokje E, van't Veer P, et al. Thyroid hormones and selenium status in breast cancer. Nutr Cancer 1997;27: 48-52.
8. Rose DP, Davis TE. Plasma thyroid-stimulating hormone and thyroxine concentrations in breast cancer. Cancer 1978; 41:666-669.
9. Takatani O, Okumoto T, Kosana H, et al. Relationship between the levels of serum thyroid hormones or oestrogen status and the risk of breast cancer genesis in Japanese women. Cancer Res 1989;49:3109-3112.
10. Lemaire M, Baugnet-Mahieu L. Thyroid function in women with breast cancer. Eur J Cancer Clin Oncol 1986;22:301-307.
11. Rasmusson B, Feedt-Rasmusen U, Hegedüs L, et al. Thyroid function in patients with breast cancer. Eur J Cancer Clin Oncol 1987;23:553-556.
12. Bhattacharya A, Vonderhaar BK. Specific binding proteins for 3,4,3′-triiodothyronine in mouse mammary epithelium. J Cell Biol 1977;75:47a.
13. Hayden TJ, Forsyth IA. Thyroid hormone binding in a rat mammary gland. J Endocrinol 1977;75:38P-39P.
14. Wilson DB, Gorewit RC. Specific thyroxine receptors in mammary cytosol from lactate cattle. Biochem Biophys Res Commun 1980;95:807-815.
15. Selliti D, Tseng Y, Latham K. Nuclear thyroid hormone receptors in C3H/HeN mouse mammary glands and spontaneous tumors. Cancer Res 1983;43:1030-1038.
16. Burke R, McGuire W. Nuclear thyroid hormone receptors in a human breast cancer cell line. Cancer Res 1978;38:3769-3773.
17. Smallridge RC, Latham KR. Nuclear thyroid hormone receptor in human breast tumors. Clin Res 1980;28:421.
18. Eil C, Douglass EC, Rosenberg SM, Kano-Sueoka T. Receptor characteristics of the rat mammary carcinoma cell line 64-21. Cancer Res 1981;41:42-48.
19. Cerbon MA, Pichon MF, Milgrom E. Thyroid hormone receptors in human breast cancer. Cancer Res 1981;41:4167-4173.
20. Ruzicka F, Rose D. Nuclear thyroid hormone receptors, α-glycerophosphate dehydrogenases, and malic enzyme in N-nitrosomethylurea-induced rat mammary tumors. Cancer Res 1983;43:3150-3154.
21. Sap J, Muñoz A, Damm K, et al. The c-erb-A protein is a high-affinity receptor for thyroid hormone. Nature 1986;324:635-640.
22. Weinberger C, Thomson CC, Ong ES, Lebo R, Gruol DJ, Evans RM. The c-erbA encodes a thyroid hormone receptor. Nature 1986;324:641-646.
23. van de Vijver M, van de Bersselaar R, Devilee P, Cornelisse C, Peterse J, Nusse R. Amplification of the neu (c-erbB-2) oncogene in human mammary tumors is relatively frequent and is often accompanied by amplification of the linked c-erbA oncogene. Mol Cell Biol 1987;7:2019-2023.
24. Ali IU, Lidereau R, Callahan R. Presence of two members of c-erbA receptor gene family (c-erbAβ and c-erbA2) in smallest region of somatic homozygosity on chromosome 3p21-p25 in human breast carcinoma. J Natl Cancer Inst 1989;81:1815-1820.
25. Futreal PA, Söderkvist P, Marks JR, et al. Detection of frequent allelic loss on proximal chromosome 17q in sporadic breast carcinoma using microsatellite length polymorphism. Cancer Res 1992;52:2624-2627.
26. Dobrovik A, Houle B, Belouchi A, Bradley WEC. Erb-A related genes coding for DNA-binding hormone receptors localized to chromosome 3p21-3p25 and deleted in small cell lung carcinoma. Cancer Res 1988;48:682-685.
27. Markowitz S, Haut M, Stellato T, Gerbic C, Molkentin K. Expression of the erbA-β class of thyroid hormone receptors is selectively lost in human colon carcinoma. J Clin Invest 1989; 84:1683-1687.
28. Yokota J, Yamamoto T, Miyajima N, et al. Genetic alterations of the c-erbB-2 oncogene occur frequently in tubular adenocarcinoma of the stomach and are often accompanied by amplification of the v-erbA homologue. Oncogene 1988;2:283-287.
29. Arbuthnot P, Kew M, Parker I, Fitschen W. Expression of c-erbA in human hepatocellular carcinomas. Anticancer Res 1989;9:885-888.
30. Dayton AI, Selden JR, Laws G, et al. A human c-erbA oncogene homologue is closely proximal to the chromosome 17 breakpoint in acute promyelocytic leukemia. Proc Natl Acad Sci USA 1988;81:4495-4499.
31. López-Barahona M, Fialka I, González-Sancho JM, et al. Thyroid hormone regulates stromelysin expression, protease secretion and the morphogenetic potential of normal polarized mammary epithelial cells. EMBO J 1995;14:1145-1155.
32. Lin KH, Zhu XG, Shieh HY, et al. Identification of naturally occurring dominant negative mutants of thyroid hormone α1 and β1 receptors in a human hepatocellular carcinoma cell line. Endocrinology 1996;137:4073-4081.
33. Erickson HP. Tenascin-C, tenascin-R and tenascin-X: A family of talented proteins in search of functions. Curr Opin Cell Biol 1993;5:869-876.
34. Chiquet-Ehrismann R, Hagios C, Schenk S. The complexity in regulating the expression of tenascins. BioEssays 1995;17:873-878.
35. End P, Panayotou G, Entwistle A, Waterfield MD, Chiquet M. Tenascin: A modulator of cell growth. Eur J Biochem 1992;209:1041-1051.
36. Chiquet-Ehrismann R. Inhibition of cell adhesion by anti-adhesive molecules. Curr Opin Cell Biol 1995;7:715-719.
37. Rüegg CR, Chiquet-Ehrismann R, Alkan SS. Tenascin, an extracellular matrix protein, exerts immunomodulatory activities. Proc Natl Acad Sci USA 1989;86:7437-7441.
38. Canfield AE, Schor AM. Evidence that tenascin and thrombospondin-1 modulate sprouting of endothelial cells. J Cell Sci 1995;108:797-809.
39. Zagzag D, Friedlander DR, Dosik J, et al. Tenascin-C expression by angiogenic vessels in human astrocytomas and by human brain endothelial cells in vitro. Cancer Res 1996;56:182-189.
40. Mackie EJ, Chiquet-Ehrismann R, Pearson CA, et al. Tenascin is a stromal marker for epithelial malignancy in the mammary gland. Proc Natl Acad Sci USA 1987;84:4621-4625.
41. Koukoulis GK, Gould VE, Bhattacharyya A, Gould JE, Howeedy AA, Virtanen I. Tenascin in normal, reactive, hyperplastic, and neoplastic tissues: Biologic and pathologic implications. Hum Pathol 1991;22:636-643.
42. Borsi L, Carnemolla B, Nicolò G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer 1992;52:688-692.
43. Chiquet-Ehrismann R. Tenascin and other adhesion-modulating proteins in cancer. Semin Cancer Biol 1993;4:301-310.
44. Riedl S, Bodenmuller H, Hinz U, et al. Significance of tenascin serum level as tumor marker in primary colorectal carcinoma. Int J Cancer 1995;64:65-69.
45. Schienk S, Lienard D, Gerain J, et al. Rapid increase in plasma tenascin-C concentration after isolated limb perfusion with high-dose tumor necrosis factor (TNF), interferon gamma (IFN gamma) and melphalan for regionally advanced tumors. Int J Cancer 1995;63:665-672.
46. Yoshida T, Ishihara A, Hirokawa Y, Kusakabe M, Sakakura T. Tenascin in breast cancer development - is epithelial tenascin a marker for poor prognosis? Cancer Lett 1995;90:65-73.
47. Jahkola T, Toivionen T, von Smitten K, Blomqvist C, Virtanen I. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer 1996;69:445-447.
48. Lightner VA, Marks JR, McCachren SS. Epithelial cells are an important source of tenascin in normal and malignant human breast tissue. Exp Cell Res 1994;210:177-184.
49. Wirl G, Hermann M, Ekblom P, Fässler R. Mammary epithelial cell differentiation in vitro is regulated by an interplay of EGF action and tenascin-C downregulation. J Cell Sci 1995;108:2445-2456.
50. Jones PL, Boudreau N, Myers CA, Erickson HP, Bissell MJ. Tenascin-C inhibits extracellular matrix-dependent gene expression in mammary epithelial cells. J Cell Sci 1995;108:519-527.
51. Vollmer G, Michna H, Ebert K, Knuppen R. Down-regulation of tenascin expression by antiprogestins during terminal differentiation of rat mammary tumors. Cancer Res 1992;52:4642-4648.
52. Alvarez-Dolado M, González-Sancho JM, Bernal J, Muñoz A. Developmental expression of tenascin-C is altered by hypothy-roidism in the rat brain. Neuroscience 1998;84:309-322.
53. Reichmann E, Ball R, Groner B, Friis RR. New mammary epithelial and fibroblastic clones in coculture form structures competent to differentiate functionally. J Cell Biol 1989;108:1127-1138.
54. Linial M, Gunderson N, Groudine M. Enhanced transcription of c-myc in bursal lymphoma cells requires continuous protein synthesis. Science 1985;230:1126-1132.
55. Chomczynski P, Sacchi N. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 1987;162:156-159.
56. Koenig RJ, Lazar MA, Hodin RA, et al. Inhibition of thyroid hormone action by a non-hormone binding c-erbA protein generated by alternative mRNA splicing. Nature 1989;337:659-661.
57. Lazar MA, Hodin RA, Chin WW. Human carboxyl-terminal variant of α-type c-erbA inhibits trans-activation by thyroid hormone receptors without binding thyroid hormone. Proc Natl Acad Sci USA 1989;88:7771-7774.
58. Roskelley CD, Srebrow A, Bissell MJ. A hierarchy of ECM-mediated signalling regulates tissue-specific gene expression. Curr Opin Cell Biol 1995;7:736-747.
59. Ekblom M, Fässler R, Tomasmi-Johansson B, Nilsson K, Ekblom P. Downregulation of tenascin expression by glucocorticoids in bone marrow stromal cells and in fibroblasts. J Cell Biol 1993;123:1037-1045.
60. Sakai T, Kawakatsu H, Furukawa Y, Saito M. Regulation of EGF-induced tenascin-C by steroids in tenascin-C-non-producing human carcinoma cells. Int J Cancer 1995;63: 720-725.
61. Caelles C, González-Sancho JM, Muñoz A. Nuclear hormone receptor antagonism with AP-1 by inhibition of the JNK pathway. Genes Dev 1997;11:3351-3364.
62. Yap N, Yu C-L, Cheng S-Y. Modulation of the transcriptional activity of thyroid hormone receptors by the tumor suppressor p53. Proc Natl Acad Sci USA 1995;93:4273-4277.
63. Qi J-S, Desai-Yajnik V, Yuan Y, Samuels HH. Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression. Mol Cell Biol 1997;17:7195-7207.
64. Yokoe T, Iino I, Takei H, et al. Relationship between thyroid-pituitary function and response to therapy in patients with recurrent breast cancer. Anticancer Res 1996;16:2069-2072.